Drug Trial Radar · NCT05053152
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
194
Planned (sponsor's estimate)
Start
Apr 20, 2022
Primary completion
Feb 1, 2029
Study completion Feb 1, 2034
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Conditions
- Oligometastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Ductal Adenocarcinoma
- Prostate Intraductal Carcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo urine and blood sample collection
Bone ScanProcedure
Undergo bone scan
Computed TomographyProcedure
Undergo CT and/or PET/CT
Fluciclovine F18Other
Given fluciclovine F18
Magnetic Resonance ImagingProcedure
Undergo MRI and/or PET/MRI
Placebo AdministrationDrug
Given PO
Positron Emission TomographyProcedure
Undergo PET/CT and/or PET/MRI
PSMA PET ScanProcedure
Undergo PSMA PET/CT or PET/MRI
RelugolixDrug
Given PO
Stereotactic Body Radiation TherapyRadiation
Undergo SABR
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiological progression-free survival (rPFS)Time frame: Time from randomization to the occurrence of radiological progression detected by conventional imaging or death from any cause, assessed up to 5 years
Locations
245 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Center at Saint Joseph's
Phoenix, Arizona
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Tower Cancer Research Foundation
Beverly Hills, California
Marin General Hospital
Greenbrae, California
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Memorial Medical Center
Modesto, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Sutter Medical Center Sacramento
Sacramento, California
Sutter Pacific Medical Foundation
Santa Rosa, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
UCHealth University of Colorado Hospital
Aurora, Colorado
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado
UCHealth Memorial Hospital Central
Colorado Springs, Colorado
Memorial Hospital North
Colorado Springs, Colorado
AdventHealth Porter
Denver, Colorado
Shaw Cancer Center
Edwards, Colorado
Poudre Valley Hospital
Fort Collins, Colorado
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado
Banner North Colorado Medical Center
Greeley, Colorado
UCHealth Greeley Hospital
Greeley, Colorado
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado
AdventHealth Littleton
Littleton, Colorado
Medical Center of the Rockies
Loveland, Colorado
Banner North Colorado Medical Center - Loveland Campus
Loveland, Colorado
AdventHealth Parker
Parker, Colorado
Beebe South Coastal Health Campus
Millville, Delaware
Helen F Graham Cancer Center
Newark, Delaware
Medical Oncology Hematology Consultants PA
Newark, Delaware
Beebe Health Campus
Rehoboth Beach, Delaware
George Washington University Medical Center
Washington D.C., District of Columbia
AdventHealth Altamonte
Altamonte Springs, Florida
AdventHealth Celebration
Celebration, Florida
Jupiter Medical Center
Jupiter, Florida
GenesisCare USA - Lakewood Ranch
Lakewood Rch, Florida
AdventHealth Orlando
Orlando, Florida
GenesisCare USA - Plantation
Plantation, Florida
Moffitt Cancer Center at SouthShore
Ruskin, Florida
Showing 40 of 245 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.